Skip to main content

Table 1 Characteristics of the TR clonotypes analyzed in this study

From: Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients

  number of         
Clono type seq a subjects/patients (patients ID) b HLA vaccination   source type of sequenced cells specificity c TRBV selection references
Mel/M-A 47 90 5 (8,22, 15, 30, 38) A2 modified Melan-A pre/postd PBL T-cell clones Melan-A* no in preparation
  6 6 1 (VER) A2 no   PBL T-cell clones Melan-A* no 5
  26 27 3 (M199, M180, M138) A2 no   TIL T-cell clones Melan-A * no 6
  11 11 10 (Mela01, 02, 03, 04, 05, 06, 10, 13, 15, 16) A2 modified Melan-A CTL clones pre PBL T-cell clones Melan-A*** no 7
  2 17 2 (-)e A2 no   TIL CTL lines Melan-A**** 4, 28 10
  30 119 3 (1, 2, 3) A2 no   PBL/TIL CTL lines Melan-A**** 7, 20, 29, 12, 5 11
  18 54 2 (LAU 181,203) A2 no   TIL CD8-sorted cells Melan-A* 27, 30 12
  7 7 3 (NW28, 29, 30) A2 Melan-A, Tyrosinase, gp100 pre/post PBL CD8-sorted cells Melan-A* no 13
  27 50 1 (-) A2 no   PBL/TIL T-cell clones Melan-A* no 14
  9 10 3 (SK9-AV, M77, LB373) A2 no   PBL/TIL T-cell clones Melan-A** no 15
  8 9 5 (8959, LB39, AV, 501, 9742) A2 no   PBL/TIL T-cell clones Melan-A**** no 16
  12 27 1 (LAU444) A2 modified Melan-A pre/post TIL/PBL CD8-sorted cells Melan-A* 6, 28 17
  7 17 1 (LAU337) A2 Melan-A post PBL T-cell clones Melan-A* no 18
  210 444          
Ctrl/M-A 53 53 3 (HD421, HD009, T12) A2 NA   PBL/Thymocytes T-cell clones Melan-A* no 5
  32 37 1 (PSA) A2 NA   PBL T-cell clones Melan-A* no 8
  28 28 4 (HD001, HD002, HD010, CB886) Various A2- NA   PBL CD8-sorted cells Melan-A* no 19
  113 118          
  4 8 1 (-) A2, A24 peptide-pulsed DCf post PBL/TIL - - no 22
Mel/noM-A 1 - Patient 1 A11, A32 IL-7+ autologous melanoma cells pre/post PBL/TIL/DTH - - 27 23
  2 2 1 (FON) A2, A29 no   TIL T-cell clones autologous melanoma no 24
  4 9 1 (MZ2) Cw16 MNNG-treated melanoma cells pre/post PBL T-cell clones BAGE, MAGE1 no 25
  7 140 1 (-) - no   TIL/PBL/Skin - - 14, 29, 23 26
  9 40 1 (-) B14 no   TIL/Tissue T-cell clones/lines/TIL - 6 27
  25 42 6 (20113, 20297,20254, 20249, 20360, 20063) - DNP-modified melanoma cells post TIL in metastases - - no 28
  6 38 1 (til 620) - no   TIL T-cell colture Melan-A/gp100 20, 19, 13 29
  52 87 4 (1, 2, 5, 6) A2 no   TIL, PBL, normal skin - - 27, 9, 20, 29, 28, 7 30
  11 42 1 (2)   autologous stem cells after CTX pre/post PBL - - 2 31
  3 3 2 (BON, MAR) A2, A25 no   TIL - - 28, 2, 24 32
  3 3 1 (MZ2) A1 autologous melanoma cells   PBL T-cell clones MAGE1 no 33
  5 10 1 (9742) A2 no   PBL/TIL T-cell clones, PBL-PHA autologous melanoma no 34
  19 38 1 (JB) A1, A28 DNP-modified melanoma cells post TIL - autologous melanoma 27 35
  4 15 2 (1200, 501) A1, A2 no   TIL bulk/CTL microcultures A1/A2+ melanoma cells no 36
  22 172 3 (1622, 1464, 1214) A24, 26; A3, 11, A24 no   Tissue - - 6, 27, 28, 24, 10 37
  1 1 1 (0831) A2 no   TIL - - 8 38
  16 100 5 (1, 2, 3, 4, 6) - no   Tissue - - 4, 28, 25, 29 39
  1 15 1 (LB256) A2 no   PBL T-cell clones gp100 no 40
  4 192 1 (1803) A1 no   TIL bulk + cultures - 20 41
  199 957          
Ctrl/HLA-A2+ 41 46 15 (BD, CL, DD, DP, HL, JE, JM, JN, JW, KD, KE, MO, MP, NM, SW) A2 NA   PBL T-cell clones M58-66 (flu) 19 42
  56g 606 12 (PB1, PB2, PB3, PB4, RA1, RA2, RA3, RA4, RA5, RA11, RA14, RA15) A2 NA   PBL/SFL T-cell clones/CD8-sorted lines GLC/A2 (EBV) 2, 20, 29, 9, 14 43
  9 9 2 (FM, JM) A2 NA   PBL T-cell lines M57-68 (flu) no 44
  42 - 5 (B, F, M, P, T) A2 NA   PBL CTL/CD8-sorted population GL9 (EBV) no 45
  79 - 9 (D, F, H, K, M, N, P, R, S) A2 NA   PBL CTL/CD8-sorted cells NV9 (CMV)   45
  33 43 4 (BMT, HD, RA, KT) A2 NA   PBL/SFL T-cell clones pp65 (NLV/A2, HCMV) no 46
  5 92 3 (003, 065, 868) A2 NA   PBL T-cell lines/clones/CD8-sorted cells GAG (HIV), POL(HIV) 28, 5, 12 47
  1 7 1 (HEU) A2 NA   TIL T-cell clones lung cancer antigen no 48
  3 31 1 (HEU) A2 NA   TIL/PBL T-cell clones alpha-actinin-4 no 49
  14 28 2 (-, 5H13) A2 NA   PBL T-cell clones mHag HA-2 no 50
  9 15 1 (2) A2 NA   PBL CD8-sorted cells 19-kDa M. tuberculosis no 51
  6 9 1 (-) A2 NA   TIL T-cell clones various tumor epitopes no 52
  2 29 1 (LB37) A2 NA   PBL CD8-sorted cells mutated malic enzyme no 53
  5 24 2 (MS2, MS7) A2 NA   PBL T-cell culture TALpep no 54
  305 939          
  1. a Number of sequences from which the clonotypes have been selected.
  2. b Abbreviations: CTL: Cytotoxic T Lymphocytes; CTX: Chemotherapy; DNP: Dinitrophenyl; DTH: delayed-type hypersensitivity site: ID: Identification number; MNNG: N-methyl-N'-nitro-N-nitrosoguanidine; NA: not applicable; Seq: sequences; SFL: synovial fluid lymphocytes; TIL: Tissue infiltrating lymphocytes.
  3. c CTL specificity against modified Melan-A analyzed by *multimers; ** competition assay; *** production of IL-2 in response to HLA-A2 Melan-A-expressing melanoma cell lines **** or CTL specificity against natural Melan-A analyzed by 51Cr release assay.
  4. d Clonotypes identified either in pre or in post vaccination.
  5. e -: data not available.
  6. f MAGE-4, MAGE-10, GnTV, gp100, Melan-A, FluMP, FluBNP-pulsed dendritic cells.
  7. g Identical clonotypes are included if found in different patients.
  8. Bold: total number of clonotypes and of sequenced TRBV chains in each group